Triple therapy was effective and well-tolerated in symptomatic moderate-to-severe chronic obstructive pulmonary disease (COPD), even among GOLD B patients with a lower risk of exacerbations, results of the manufacturer-sponsored KRONOS trial found.
“This makes you pause and ask the question … ‘Is a triple therapy only for people at very high risk or are some of these other things we’re seeing here potentially a benefit in our patients?'” said Ferguson.